Skip to main content

Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients with Uveal Melanoma

Trial Status: Temporarily Closed to Accrual

This phase II trial studies how well stereotactic body radiation therapy and aflibercept work in treating patients with uveal melanoma. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Aflibercept may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving stereotactic body radiation therapy followed by aflibercept may work better in treating patients with uveal melanoma.

Inclusion Criteria

  • Provide signed and dated informed consent form or have a Legally Authorized Representative (LAR) who can give consent
  • Willing to comply with all study procedures and be available for the duration of the study
  • Karnofsky performance status (KPS) >= 60
  • Diagnosed with uveal melanoma either clinically or pathologically on biopsy
  • Uveal melanoma of one eye only
  • Localized uveal melanoma, with no evidence of metastasis
  • Women of childbearing potential must have a negative urine pregnancy test within 14 days prior to enrollment

Exclusion Criteria

  • Tumor thickness more than 14 mm as measured by ultrasound
  • Active collagen vascular disease
  • Any contraindication to intravitreal injections including: elevated intraocular pressure, ocular or periocular infection, active intraocular inflammation, or other determined by treating physician
  • Known allergic reactions to components of intravitreal Aflibercept
  • Patients with known hypercoagulable syndromes
  • Prior radiation to the eye or brain
  • Life expectancy less than 6 months
  • Blind in both eyes
  • Patients unable to receive contrast enhanced brain magnetic resonance imaging (MRI)
  • Deaf in both ears
  • Patients have hypersensitivity to intravitreal Aflibercept
  • Patients is on or within 1 month of systemic anti-VEGF treatment
  • Pregnancy or active breastfeeding. Sexually active men or women of childbearing potential who are unwilling to practice adequate contraception prior to the initial dose/start of the first treatment, during the study, and for at least 3 months after the last dose. Adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly * Contraception is not required for men with documented vasectomy * Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of childbearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation


Thomas Jefferson University Hospital
Contact: Wenyin Shi
Phone: 215-955-6702


I. To assess the percentage of patients able to successfully complete their prescribed treatment of radiation and intravitreal ziv-aflibercept (aflibercept) injection (IAI) with an acceptable level of toxicity.


I. To assess for reduction in the incidence of 2-year rates of radiation maculopathy, radiation papillopathy, functional vision preservation, radiation glaucoma, and to assess 2-year local control and progression-free survival.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients undergo stereotactic body radiation therapy over 5 fractions every other week day during days 1-10. Patients then receive ziv-aflibercept via intravitreal injection (IVI) on the last day of radiation therapy and then every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.

ARM B: Patients undergo stereotactic body radiation therapy as in arm A. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 4 months for up to 2 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment patients are followed up at 2 months.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Thomas Jefferson University Hospital

Principal Investigator
Wenyin Shi

  • Primary ID 18P.457
  • Secondary IDs NCI-2018-01887
  • ID NCT03712904